Compare
BeOne Medicines Ltd. vs Elanco Animal Health Inc vs Organon & Co. vs Jazz Pharmaceuticals plc
| Latest fiscal year | BeOne Medicines Ltd. ONC | Elanco Animal Health Inc ELAN | Organon & Co. OGN | Jazz Pharmaceuticals plc JAZZ |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $5.34B | $4.71B | $6.22B | $4.27B |
| Revenue growth (YoY) | +40.2% | +6.2% | -2.9% | +4.9% |
| Gross margin | 87.5% | 55.0% | 53.3% | n/a |
| Operating margin | 8.4% | n/a | n/a | -10.1% |
| Net margin | 5.4% | -4.9% | 3.0% | -8.3% |
| Net income | $286.93M | -$232.00M | $187.00M | -$356.15M |
| EPS (Diluted) | $0.19 | -$0.47 | $0.72 | -$5.84 |
| Operating cash flow | $1.13B | $560.00M | $700.00M | $1.36B |
| Free cash flow | $941.74M | $284.00M | $538.00M | $1.30B |
| Cash & equivalents | $4.55B | $545.00M | $574.00M | $1.39B |
| Total assets | $8.19B | $13.36B | $12.87B | $11.66B |
| Total liabilities | $3.83B | $6.81B | $12.12B | n/a |
| Shareholders' equity | $4.36B | $6.55B | $752.00M | $4.32B |
| Return on year-end equity | 6.6% | -3.5% | 24.9% | -8.2% |
| Shares outstanding | 1.44B | 496.98M | 260.32M | 61.44M |
Revenue, most recent five fiscal years
| Fiscal year | BeOne Medicines Ltd. | Elanco Animal Health Inc | Organon & Co. | Jazz Pharmaceuticals plc |
|---|---|---|---|---|
| Latest | $5.34B Ended 2025-12-31 | $4.71B Ended 2025-12-31 | $6.22B Ended 2025-12-31 | $4.27B Ended 2025-12-31 |
| 1 year earlier | $3.81B Ended 2024-12-31 | $4.44B Ended 2024-12-31 | $6.40B Ended 2024-12-31 | $4.07B Ended 2024-12-31 |
| 2 years earlier | $2.46B Ended 2023-12-31 | $4.42B Ended 2023-12-31 | $6.26B Ended 2023-12-31 | $3.83B Ended 2023-12-31 |
| 3 years earlier | $1.42B Ended 2022-12-31 | $4.41B Ended 2022-12-31 | $6.17B Ended 2022-12-31 | $3.66B Ended 2022-12-31 |
| 4 years earlier | $1.18B Ended 2021-12-31 | $4.76B Ended 2021-12-31 | $6.30B Ended 2021-12-31 | $3.09B Ended 2021-12-31 |